vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v11i2.233vsp-140Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ ЭТАНЕРЦЕПТА ПРИ РАННЕМ ЮВЕНИЛЬНОМ АНКИЛОЗИРУЮЩЕМ СПОНДИЛОАРТРИТЕUSE OF ETANERCEPT IN JUVENILLE ANKYLOSING SPONDILLO-ARTHRITIS WITH EARLY ONSETФетисоваА. Н.FetisovaA. N.alekatya@ya.ruАлексееваЕ. И.AlexeevaE. I.

доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центра здоровья детей РАМН, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова

Ekaterina Iosifovna Alexeeva, PhD, professor, Head of the Pediatric Department of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS

alekatya@ya.ruБзароваТ. М.BzarovaT. M.alekatya@ya.ruТайбулатовН. И.TaybulatovN. I.alekatya@ya.ruСтариковаА. В.StarikovaA. V.alekatya@ya.ruАникинА. В.AnikinA. V.alekatya@ya.ruБекджанянГ. А.BekdzhanyanG. A.alekatya@ya.ruНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health RAMS, Moscow I.M. Sechenov First Moscow State Medical UniversityRussian FederationМосковский научно-исследовательский институт глазных болезней им. ГельмгольцаРоссияThe Helmholtz Moscow Research Institute of Eye DiseasesRussian Federation201215032012112Вопросы современной педиатрии169175Copyright © Фетисова А.Н., Алексеева Е.И., Бзарова Т.М., Тайбулатов Н.И., Старикова А.В., Аникин А.В., Бекджанян Г.А., 20122012Фетисова А.Н., Алексеева Е.И., Бзарова Т.М., Тайбулатов Н.И., Старикова А.В., Аникин А.В., Бекджанян Г.А.Fetisova A.N., Alexeeva E.I., Bzarova T.M., Taybulatov N.I., Starikova A.V., Anikin A.V., Bekdzhanyan G.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/140детиювенильный анкилозирующий спондилоартритэтанерцептлечениеchildrenjuvenile ankylosing spondillo-arthritisetanercepttreatmentReferencesCassidy J. T., Petty R. E., Laxer R. M. et al. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.Cassidy J. T., Petty R. E., Laxer R. M. et al. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.Nikishina I. P. Consilium medicum — Consilium medicum. 2006; 8 (2): 20–23.Nikishina I. P. Consilium medicum — Consilium medicum. 2006; 8 (2): 20–23.Pepmueller P. H., Moore T. L. Juvenile onset spondylo arthropathies. Curr. Opin. Rheumatol. 2000; 12: 269–273.Pepmueller P. H., Moore T. L. Juvenile onset spondylo arthropathies. Curr. Opin. Rheumatol. 2000; 12: 269–273.Prier A. M. Spondyloarthropathies in childhood. Bailiere`s Clin. Rheumatol. 1998; 12: 287–307.Prier A. M. Spondyloarthropathies in childhood. Bailiere`s Clin. Rheumatol. 1998; 12: 287–307.Burgos-Vargas R., Pacheco-Tena C., Vazquez-Mellado J. Juvenileonset spondyloarthropathies. Rheum. Dis. Clin. North. Am. 1997; 23: 569–598.Burgos-Vargas R., Pacheco-Tena C., Vazquez-Mellado J. Juvenileonset spondyloarthropathies. Rheum. Dis. Clin. North. Am. 1997; 23: 569–598.Nikishina I. P. Yuvenil'nyi ankiloziruyushchii spondiloartrit. Prakticheskoe rukovodstvo po detskim boleznyam. Tom III. Pod obshchei red. V. F. Kokolinoi, A. G. Rumyantseva [Juvenile Ankylosing Spondylitis. Manual on Child Diseases. Volume 3. Edited by V. F. Kokolina, A. G. Rumyantsev]. Moscow, Medpraktika, 2004. pp. 620–649.Nikishina I. P. Yuvenil'nyi ankiloziruyushchii spondiloartrit. Prakticheskoe rukovodstvo po detskim boleznyam. Tom III. Pod obshchei red. V. F. Kokolinoi, A. G. Rumyantseva [Juvenile Ankylosing Spondylitis. Manual on Child Diseases. Volume 3. Edited by V. F. Kokolina, A. G. Rumyantsev]. Moscow, Medpraktika, 2004. pp. 620–649.Kuz'mina N. N. Yuvenil'nyi ankiloziruyushchii spondiloartrit. Detskaya revmatologiya. Rukovodstvo dlya vrachei. Pod red. A. A. Baranova, L. K. Bazhenovoi [Juvenile Ankylosing Spondylitis. Pediatric Rheumatology. Guideline. Edited by A. A. Baranov, L. K. Bazhenova]. Moscow, Meditsina, 2002. pp. 141–182.Kuz'mina N. N. Yuvenil'nyi ankiloziruyushchii spondiloartrit. Detskaya revmatologiya. Rukovodstvo dlya vrachei. Pod red. A. A. Baranova, L. K. Bazhenovoi [Juvenile Ankylosing Spondylitis. Pediatric Rheumatology. Guideline. Edited by A. A. Baranov, L. K. Bazhenova]. Moscow, Meditsina, 2002. pp. 141–182.Loginova E.Yu. Yuvenil'nyi artrit vo vzrosloi revmatologicheskoi klinike: kliniko-funktsional'naya kharakteristika i iskhody. Avtoref. dis. … kand. med. nauk [Juvenile Arthritis in Adult Rheumatologic Clinical Picture: Clinical and Functional Characteristics, Fate. Author’s abstract]. Moscow, 2001.Loginova E.Yu. Yuvenil'nyi artrit vo vzrosloi revmatologicheskoi klinike: kliniko-funktsional'naya kharakteristika i iskhody. Avtoref. dis. … kand. med. nauk [Juvenile Arthritis in Adult Rheumatologic Clinical Picture: Clinical and Functional Characteristics, Fate. Author’s abstract]. Moscow, 2001.Bowyer S., Roettcher P. and the members of the Pediatric Rheumatology Database Research Group. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. J. Rheumatol. 1996; 23: 1968–1974.Bowyer S., Roettcher P. and the members of the Pediatric Rheumatology Database Research Group. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. J. Rheumatol. 1996; 23: 1968–1974.Towner S. R., Michet C. J. Jr, O’Fallon W. M., Nelson A. M. The epidemiology of juvenile arthritis in Rochester, Minnesota 1960– 1979. Arthritis Rheum. 1983; 26: 1208–1213.Towner S. R., Michet C. J. Jr, O’Fallon W. M., Nelson A. M. The epidemiology of juvenile arthritis in Rochester, Minnesota 1960– 1979. Arthritis Rheum. 1983; 26: 1208–1213.Andersson Gare B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin. Exp. Rheumatol. 1999; 17: 367–374.Andersson Gare B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin. Exp. Rheumatol. 1999; 17: 367–374.Manners P. J., Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J. Rheumatol. 2002; 29: 1520–1530.Manners P. J., Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J. Rheumatol. 2002; 29: 1520–1530.Bochkova A. G. Consilium medicum — Consilium medicum. 2006; 8 (2).Bochkova A. G. Consilium medicum — Consilium medicum. 2006; 8 (2).Fearon U., Veale D. J. Pathogenesis of psoriatic arthritis. Clin. Exp. Dermatol. 2001; 26: 333–337.Fearon U., Veale D. J. Pathogenesis of psoriatic arthritis. Clin. Exp. Dermatol. 2001; 26: 333–337.Kalden J. R. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 2002; 4 (Suppl. 2): 534–540.Kalden J. R. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 2002; 4 (Suppl. 2): 534–540.Mease P., Kivitz A. J., Burch F. X. et al. Etanercept treatment of psoriatic arthritis: sarety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–2272.Mease P., Kivitz A. J., Burch F. X. et al. Etanercept treatment of psoriatic arthritis: sarety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–2272.Beutler B. A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.Beutler B. A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.Granfors K., Marker-Hermann E., De Kayser F. The cutting edge of spondiloarthropathy research in the millennium. Arthritis Rheum. 2002; 46 (3): 606–613.Granfors K., Marker-Hermann E., De Kayser F. The cutting edge of spondiloarthropathy research in the millennium. Arthritis Rheum. 2002; 46 (3): 606–613.Mease P., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. 2005; 64 (Suppl. 2): 78–82.Mease P., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. 2005; 64 (Suppl. 2): 78–82.Badokin V. C. Vrach — Physician. 2005; 5: 48–52.Badokin V. C. Vrach — Physician. 2005; 5: 48–52.Reed M. R., Taylor A. L. Tumor necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 2008; 38 (10): 781–789.Reed M. R., Taylor A. L. Tumor necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 2008; 38 (10): 781–789.Haibel H., Song I. H., Rudwaleit M. et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 week in daily practice. Clin. Exp. Rheumatol. 2008; 26 (2): 247–252.Haibel H., Song I. H., Rudwaleit M. et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 week in daily practice. Clin. Exp. Rheumatol. 2008; 26 (2): 247–252.Braun J., Deodhar A., Dijkmans B. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008; 59 (9): 1270–1278.Braun J., Deodhar A., Dijkmans B. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008; 59 (9): 1270–1278.Griffoul I., Giraudeau B., Mulleman D. et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine. 2009; 76 (1): 39–43.Griffoul I., Giraudeau B., Mulleman D. et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine. 2009; 76 (1): 39–43.Rumyantseva O. A. Nauchno-prakticheskaya revmatologiya — Reseach and practical rheumatology. 2006; 4: 11–19.Rumyantseva O. A. Nauchno-prakticheskaya revmatologiya — Reseach and practical rheumatology. 2006; 4: 11–19.Kozlova A. L., Alekseeva E. I., Valieva S.I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 8 (2): 20–26.Kozlova A. L., Alekseeva E. I., Valieva S.I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 8 (2): 20–26.Alekseeva E. I., Kozlova A. L., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2010; 9 (2): 23–31.Alekseeva E. I., Kozlova A. L., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2010; 9 (2): 23–31.Alekseeva E. I., Alekseeva A. M., Valieva S. I. etc. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (2): 42–54.Alekseeva E. I., Alekseeva A. M., Valieva S. I. etc. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (2): 42–54.Alekseeva E. I., Valieva S. I., Denisova R. V. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 51–57.Alekseeva E. I., Valieva S. I., Denisova R. V. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 51–57.Moreland L. W., Schiff M. H., Baumgarthner S. W. et al. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 1999; 130: 478–486.Moreland L. W., Schiff M. H., Baumgarthner S. W. et al. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 1999; 130: 478–486.Moreland L. W., Scott M. D., Baumgarther W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997; 337: 141–147.Moreland L. W., Scott M. D., Baumgarther W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997; 337: 141–147.Prince F. H., Twilt M., Ten Cate R. et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. 2008; 68 (5): 635–641.Prince F. H., Twilt M., Ten Cate R. et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. 2008; 68 (5): 635–641.Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2008; 68 (4): 519–525.Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2008; 68 (4): 519–525.Nielsen S., Ruperto N., Gerloni V. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2008; 26 (4): 688–692.Nielsen S., Ruperto N., Gerloni V. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2008; 26 (4): 688–692.Lovell D. J., Reiff A., Ilowite N. T. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.Lovell D. J., Reiff A., Ilowite N. T. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.Robinson R. F., Nahata M. C., Hayes J. R. et al. Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept. Clin. Drug. Investig. 2003; 23 (8): 511–518.Robinson R. F., Nahata M. C., Hayes J. R. et al. Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept. Clin. Drug. Investig. 2003; 23 (8): 511–518.Palazzi C., D’Angelo S., Cantini F. et al. Etanercept in spondylo arthropathies. Part I: current evidence of efficacy. Clin. Exp. Rheumatol. 2011; 29 (5): 858–64.Palazzi C., D’Angelo S., Cantini F. et al. Etanercept in spondylo arthropathies. Part I: current evidence of efficacy. Clin. Exp. Rheumatol. 2011; 29 (5): 858–64.Navarro-Sarabia F., Fernandez-Sueiro J. L., Torre-Alonso J. C., Grata cos J. et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford). 2011; 50 (10): 1828–37.Navarro-Sarabia F., Fernandez-Sueiro J. L., Torre-Alonso J. C., Grata cos J. et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford). 2011; 50 (10): 1828–37.Braun J., van der Horst-Bruinsma I. E., Huang F., BurgosVargas R. et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011; 63 (6): 1543–51.Braun J., van der Horst-Bruinsma I. E., Huang F., BurgosVargas R. et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011; 63 (6): 1543–51.

The authors declare that there are no conflicts of interest present.